Search results for "fol"

showing 10 items of 7082 documents

Emergency toe-to-hand transfer for post-traumatic finger reconstruction: A multicenter case series

2019

Abstract Background The aim of this paper was to evaluate the outcomes of a homogenous series of emergency with a toe-to-hand transfer reconstructions with a different timing: immediate (same surgical step with the debridement), primary (in the first 24 h), early (24–72 h after the debridement) or delayed (72 h-7 days). Materials and methods Between 2001 and 2011, 31 patients received an immediate reconstruction with a toe-to-hand transfer. Data on indications, timing, type of surgery, complications and outcomes (sensory and motor recovery, patient satisfaction) were extrapolated and recorded. Results Most of the procedures in our series (71%) were performed in the first 24 h. Survival rate…

AdultMalemedicine.medical_specialtyMicrosurgeryTime FactorsAdolescentSettore MED/19 - Chirurgia PlasticaThumb03 medical and health sciencesYoung AdultImmediate reconstruction0302 clinical medicinePatient satisfactionAmputation TraumaticFinger InjuriesmedicineHumansRange of Motion ArticularChildSurvival rateGeneral Environmental Science030222 orthopedicsSeries (stratigraphy)Emergency microsurgerybusiness.industryToe-to-hand transfer030208 emergency & critical care medicineRecovery of FunctionMiddle AgedPlastic Surgery ProceduresToesmedicine.disease3. Good healthSurgeryVenous thrombosisDissectionmedicine.anatomical_structureTreatment OutcomeSatisfaction rateThumbPatient SatisfactionChild PreschoolFinger reconstructionGeneral Earth and Planetary SciencesMotor recoveryFemaleEmergenciesbusinessFollow-Up Studies
researchProduct

Perinatal cerebral insults alter auditory event-related potentials.

2011

Background: Auditory event-related potentials (AERPs) can be used as indices of neural information processing. Altered AERPs have been reported in children and young adults with frontal lobe infarction. Aim: To test the hypothesis that perinatal brain injury affects cortical auditory processing. Methods: We assessed AERPs at term. 6 and 12 months of age in preterm infants [n = 9. median gestational age (GA) 27.9, range 23.9-30.0 wk], term infants with perinatal intracerebral hemorrhage (ICH) [n = 5, GA 40.3, range 37.4-42.3 wk], and term infants with perinatal asphyxia In [n = 4. GA 39.4. range 37.9-40.3 wk]. Healthy preterm (n = 16) and term infants (n = 22) served as controls. A harmonic …

AdultMalemedicine.medical_specialtyMismatch negativityInfant Newborn DiseasesCentral nervous system disease03 medical and health sciencesYoung Adult0302 clinical medicinePregnancy030225 pediatricsInternal medicinemedicineHumansYoung adultCerebral HemorrhageIntracerebral hemorrhageAsphyxiaAuditory CortexInfant NewbornObstetrics and GynecologyGestational agemedicine.diseasePrognosisSurgeryPerinatal asphyxiaFrontal lobeAcoustic StimulationBrain InjuriesPediatrics Perinatology and Child HealthCardiologyEvoked Potentials AuditoryFemalemedicine.symptomPsychology030217 neurology & neurosurgeryInfant PrematureFollow-Up StudiesEarly human development
researchProduct

Systemic moxifloxacin vs amoxicillin/metronidazole adjunct to non-surgical treatment in generalized aggressive periodontitis

2014

Background: The objective of this randomized clinical study was to evaluate the effect of systemic administration of moxifloxacin compared to amoxicillin and metronidazole, combined with non-surgical treatment in patients with generalized aggressive periodontitis (GAgP) in a 6-month follow-up. Material and Methods: A total of 39 systemically healthy patients with GAgP were evaluated in this randomized clinical trial. Periodontal parameters were recorded at the baseline during the 1 st , 3 rd and 6 th month. Patients received either 400 mg of moxifloxacin per os once daily or 500 mg of metronidazole and 500 mg amoxicillin per os three times daily for 7 days consecutively. Results: No signifi…

AdultMalemedicine.medical_specialtyMoxifloxacinOdontologíaGastroenterologylaw.inventionYoung AdultPharmacotherapyRandomized controlled trialAnti-Infective AgentslawMoxifloxacinInternal medicineMetronidazoleMedicineAggressive periodontitisHumansAdverse effectGeneral DentistryOral Medicine and Pathologybusiness.industryResearchAmoxicillinAmoxicillin:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseCiencias de la saludSurgeryMetronidazoleOtorhinolaryngologyAggressive PeriodontitisUNESCO::CIENCIAS MÉDICASSystemic administrationSurgeryDrug Therapy CombinationFemalebusinessmedicine.drugFluoroquinolonesFollow-Up Studies
researchProduct

Blood lipids, homocysteine, stress factors, and vitamins in clinically stable multiple sclerosis patients

2009

Abstract Multiple Sclerosis (MS) patients present a decrease of antioxidants and neuroprotective and immunoregulatory vitamins and an increase of total homocysteine (tHcy), cholesterol (CHL), HDL-cholesterol, and of cellular stress markers, variably associated with the different phases of the disease. We compared the blood levels of uric acid, folic acid, vitamins B12, A, and E, tHcy, CHL, HDL-cholesterol, and triglycerides in forty MS patients during a phase of clinical inactivity with those of eighty healthy controls, matched for age and sex. We found higher levels of tHcy (p = 0.032) and of HDL-cholesterol (p = 0.001) and lower levels of vitamin E (p = 0.001) and the ratio vitamin E/CHL …

AdultMalemedicine.medical_specialtyMultiple SclerosisAdolescentHomocysteineEndocrinology Diabetes and Metabolismmedicine.medical_treatmentClinical BiochemistryBlood lipidsClinical nutritionBiologyAntioxidantschemistry.chemical_compoundFolic AcidEndocrinologyHigh-density lipoproteinSettore BIO/10 - BiochimicaInternal medicinemedicineHumansShort PaperVitamin B12Homocysteinelcsh:RC620-627TriglyceridesBiochemistry medicalCholesterolVitamin EBiochemistry (medical)VitaminsMiddle AgedLipidsUric Acidlcsh:Nutritional diseases. Deficiency diseasesEndocrinologychemistryCase-Control StudiesUric acidSettore MED/26 - NeurologiaFemalelipids (amino acids peptides and proteins)Lipids in Health and Disease
researchProduct

High Prevalence and Fast Rising Incidence of Multiple Sclerosis in Caltanissetta, Sicily, Southern Italy

2006

<i>Background:</i> Epidemiological studies conducted in Sicily and Sardinia, the two major Mediterranean islands, showed elevated incidence and prevalence of multiple sclerosis (MS)and a recent increase in disease frequency. <i>Objective:</i> To confirm the central highlands of Sicily as areas of increasing MS prevalence and elevated incidence, we performed a follow-up study based on the town of Caltanissetta (Sicily), southern Italy. <i>Methods:</i> We made a formal diagnostic reappraisal of all living patients found in the previous study performed in 1981. All possible information sources were used to search for patients affected by MS diagnosed accordi…

AdultMalemedicine.medical_specialtyMultiple SclerosisAdolescentMultiple sclerosis incidence Prevalence SicilyEpidemiologyAge DistributionEpidemiologyPrevalencemedicineHumansSex DistributionSicilyAgedHigh prevalencebusiness.industryIncidenceMultiple sclerosisIncidence (epidemiology)Urban HealthMiddle Agedmedicine.diseaseHealth SurveyshumanitiesFemaleSettore MED/26 - NeurologiaNeurology (clinical)businessMediterranean IslandsFollow-Up StudiesDemographyNeuroepidemiology
researchProduct

Alemtuzumab treatment of multiple sclerosis in real-world clinical practice: A report from a single Italian center

2020

Abstract Background Alemtuzumab, is a compound approved for highly active MS, and, in Europe, employed after the use of other disease-modifying treatments (DMTs) with an escalation approach or used as a first therapeutic option. The occurrence of secondary autoimmune adverse events and or infections can differ depending on the employed approach. Objective To evaluate the efficacy and safety of alemtuzumab in real-world MS population that encompassed patients previously treated with other DMTs. Methods 35 patients, treated with alemtuzumab in a single MS Center, were followed for at least 36 months. The study investigated the prevalence of patients reaching the phase of the non-active diseas…

AdultMalemedicine.medical_specialtyMultiple SclerosisEfficacyPopulationDisease03 medical and health sciences0302 clinical medicineInternal medicinePost-hoc analysisOutcome Assessment Health CaremedicineHumansImmunologic Factors030212 general & internal medicineAdverse effecteducationAlemtuzumabeducation.field_of_studybusiness.industryMultiple sclerosisGeneral MedicineMiddle Agedmedicine.diseasePancytopeniaProgression-Free SurvivalNeurologyItalyAdverse eventsDisease ProgressionAlemtuzumabFemaleSettore MED/26 - NeurologiaNeurology (clinical)Autoimmune hemolytic anemiaSafetybusiness030217 neurology & neurosurgerymedicine.drugFollow-Up Studies
researchProduct

Ten-year follow-up of health-related quality of life among ambulatory persons with multiple sclerosis at baseline

2016

Purpose The aim of this 10-year follow-up study was to determine changes in health-related quality of life (HRQoL) over time among ambulatory persons with MS (PwMS) at the baseline using generic and disease-specific instruments. Methods Of 109 independently walking PwMS included in a population-based study in 2002, 77 (70.6 %) were re-assessed in 2012. HRQoL was captured using the 36-Item Short Form Survey Instrument (RAND-36), 15D instrument (15D), and the Multiple Sclerosis Quality of Life-54 (MSQOL-54). Repeated-measures ANOVA and effect size (ES) calculations (Cohen’s d) were used in the statistical analysis. Results The RAND-36 physical health composite score (p = 0.003, ES = 0.26) and…

AdultMalemedicine.medical_specialtyMultiple SclerosisTime FactorsPopulationelämänlaatu03 medical and health sciences0302 clinical medicinePhysical medicine and rehabilitationQuality of lifeMS-tautiSickness Impact ProfileSurveys and QuestionnairesmedicineHumans030212 general & internal medicinePatient Reported Outcome MeasureseducationSocial functioningAgedHealth related quality of lifeAged 80 and overeducation.field_of_studySexual functioningbusiness.industryMultiple sclerosisPublic Health Environmental and Occupational HealthMiddle Agedmedicine.diseasepatient-reported outcomesAmbulatoryPhysical therapyFemaleAnalysis of variancebusinessterveys030217 neurology & neurosurgeryFollow-Up Studies
researchProduct

Autoantibodies to the islet antigen ICA69 occur in IDDM and in rheumatoid arthritis.

1995

Islet cell antigen (ICA) 69 is a newly-recognized islet cell antigen to which autoantibodies have been observed in prediabetic relatives of patients with insulin-dependent-diabetes mellitus (IDDM). Here we extend the earlier analysis of ICA69 antibodies to patients with recent-onset IDDM and to patients with other immune-mediated diseases. ICA69 antibodies were determined by Western blot using an affinity purified recombinant fusion protein of ICA69 and maltose binding protein. ICA69 antibody quantities were determined as titres using a titration curve of a standard serum as reference. Mean logarithmic ICA69 antibody titres were 3.4 (+/- 1.4) in 99 patients with acute IDDM compared to 2.8 (…

AdultMalemedicine.medical_specialtyMultiple SclerosisTime Factorsendocrine system diseasesAdolescentEndocrinology Diabetes and MetabolismRecombinant Fusion ProteinsBlotting WesternArthritisAutoantigensArthritis RheumatoidAntigenCrohn DiseaseInternal medicineImmunopathologyInternal MedicinemedicineHumansFamilyChildAutoantibodiesAutoimmune diseasegeographygeography.geographical_feature_categorybiologybusiness.industryAutoantibodyThyroiditis AutoimmuneInfantMiddle AgedIsletmedicine.diseaseGraves DiseaseEndocrinologyDiabetes Mellitus Type 1Rheumatoid arthritisChild PreschoolImmunologybiology.proteinColitis UlcerativeFemaleAntibodybusinessFollow-Up StudiesDiabetologia
researchProduct

"Baseline physical functioning status of metastatic colorectal cancer patients predicts the overall survival but not the activity of a front-line oxa…

2010

BACKGROUND: No differences in response rate (RR), progression-free survival (PFS), overall survival (OS) and quality of life (QoL) were seen in patients randomly treated with biweekly oxaliplatin plus either fluorouracil/folinic acid or capecitabine. METHODS: We investigated the independent effect of baseline clinical characteristics and physical functioning (PF) domain on RR, PFS, and OS in 310 patients who completed the EORTC QLQ-C30 questionnaire. Multivariate analyses stratified by treatment were performed. An exploratory analysis was done by grouping patients with a PF score superior or equal to the highest quartile (n = 111), included between the highest and the lowest quartiles (n = …

AdultMalemedicine.medical_specialtyMultivariate analysisColorectal cancerSettore MED/06 - Oncologia MedicaKaplan-Meier EstimateGastroenterologyDisease-Free SurvivalCapecitabineTreatment Outcome; Prognosis; Aged 80 and over; Male; Retrospective Studies; Randomized Controlled Trials as Topic; Middle Aged; Kaplan-Meier Estimate; Colorectal Neoplasms; Female; Disease-Free Survival; Humans; Quality of Life; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials Phase III as Topic; Aged; Adult; Health Status Indicators; Multicenter Studies as TopicFolinic acidQuality of lifeInternal medicineAntineoplastic Combined Chemotherapy Protocols80 and overmedicineOverall survivalHealth Status IndicatorsHumansMulticenter Studies as TopicClinical TrialsRadiology Nuclear Medicine and imagingneoplasmsmetastatic colorectal canceroxaliplatin physical functioning statusAgedRandomized Controlled Trials as TopicRetrospective StudiesAged 80 and overbusiness.industryHematologyGeneral MedicineMiddle AgedPrognosismedicine.diseaseSurgeryOxaliplatinPhase III as TopicTreatment OutcomeClinical Trials Phase III as TopicOncologyQuartileQuality of LifeFemaleColorectal Neoplasmsbusinessmedicine.drug
researchProduct

Efficacy of different rituximab therapeutic strategies in patients with neuromyelitis optica spectrum disorders

2019

Abstract Objective To evaluate disease activity according to rituximab (RTX) induction and maintenance regimens in a multicenter real-life dataset of NMOSD patients. Methods This is an observational-retrospective multicentre study including patients with NMOSD treated with RTX in 21 Italian and 1 Swiss centers. Demographics, relapse rate and adverse events over the follow-up were summarized taking into account induction strategy (two-1 g infusions at a 15-day interval (IND-A) vs. 375 mg/m2/week infusions for one month (IND-B)) and maintenance therapy (regimen A (M-A) with fixed time-points infusions vs. regimen B (M-B) based on cytofluorimetric driven reinfusion regimens, the least further …

AdultMalemedicine.medical_specialtyMultivariate analysisEfficacyOutcome and Process AssessmentSettore MED/2603 medical and health sciences0302 clinical medicineMaintenance therapyInternal medicinemedicineHumansImmunologic FactorsIn patient030212 general & internal medicineAdverse effectAgedRetrospective StudiesNeuromyelitis opticabusiness.industryMultiple sclerosisGeneral MedicineMiddle Agedmedicine.diseaseNeuromyelitis opticaHealth CareRegimenOutcome and Process Assessment Health CareNeurologyEfficacy Neuromyelitis optica RituximabRituximabFemaleNeurology (clinical)businessRituximab030217 neurology & neurosurgerymedicine.drugFollow-Up Studies
researchProduct